1355. The SARS-CoV-2 Monoclonal Antibody AZD3152 Potently Neutralizes Historical and Emerging Variants and is Being Developed for the Prevention and Treatment of COVID-19 in High-risk Individuals

BACKGROUND: EVUSHELD was developed for the prevention and treatment of mild-to-moderate COVID-19 for high-risk individuals. However, the SARS-CoV-2 virus continues to evolve in the presence of natural- and vaccine-acquired immunity, escaping previously authorized antibody therapies such as bebtelovi...

Descripción completa

Detalles Bibliográficos
Autores principales: Francica, Joseph R, Cai, Yingyun, Diallo, Seme, Rosenthal, Kim, Ren, Kuishu, Flores, Daniel J, Dippel, Andrew, Wu, Yuling, Chen, Xiaoru, Cantu, Erin, Choudhary, Rakesh, Sulikowski, Michal, Adissu, Hibret, Chawla, Bhavna, Kar, Swagata, van Dyk, Nydia, Oganesyan, Vaheh, Rajan, Saravanan, Ryan, Patricia C, Loo, Yueh-Ming, Cohen, Taylor, Esser, Mark T, Blair, Wade
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676859/
http://dx.doi.org/10.1093/ofid/ofad500.1192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676859/
http://dx.doi.org/10.1093/ofid/ofad500.1192

Ejemplares similares